MDLN Medline Inc. Insider Trading

CCO Douglas P Golwas sells 100,000 shares ($3.7M) via 10b5-1 plan; retains 365,864 shares as Common Units.

Douglas P Golwas, Chief Commercial Officer, executed 2 separate sales totaling 100,000 shares for $3,677,115.30 on 2026-06-16 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-11. The sales reduced his non-derivative holdings from 465,864 shares to 365,864 shares, a -21.5% reduction in that portion of his position. The stock currently trades at $36.42, down 28.4% from its 52-week high of $50.88. The company reported revenue of $7,352,000,000.00 in the latest quarter with annual revenue growth of +11.5%, reflecting solid operational performance independent of near-term share price movements. As a scheduled transaction under a pre-established plan rather than a discretionary sale, this filing reflects adherence to a predetermined execution schedule.

Principal Accounting Officer Jessi L Corcoran bought 5,000 shares of MDLN at $34.15; stock now at $36.01, down -8.9% in 30 days and -15.0% in 90 days.

Jessi L Corcoran, Principal Accounting Officer at Medline Inc., purchased 5,000 shares at $34.15 for a total value of $170,750.00, building an initial position in the company. The stock has traded at $36.01 as of the filing analysis date, representing a modest gain from the transaction price, though it remains -29.2% from its 52-week high of $50.88. Over the preceding 30 days the stock declined -8.9%, and over 90 days it declined -15.0%. Medline's fundamentals show $7.4B in latest quarterly revenue with $239.0M net income and annual revenue growth of +11.5%, providing context for the company's underlying operational scale. The purchase by a senior finance officer during a period of share price weakness merits attention to track whether this activity patterns with future insider behavior or material developments.

10% owner Hellman & Friedman sold 31,868,237 shares ($1.2B) on 2026-05-28; retains 6,377,698 shares post-transaction.

Hellman & Friedman Capital Partners X (Parallel), LP executed 4 separate sales totaling 31,868,237 shares for $1,164,385,709.40 at $36.54 on 2026-05-28, reducing its stake from 38,245,935 shares to 6,377,698 shares (an -83.3% reduction in holdings). The timing occurs with the stock currently at $35.75, down -29.7% from its 52-week high of $50.88 and down -20.1% over the past 30 days. Reviewing the insider's same-ticker history at MDLN, 4 of 5 prior sells were well-timed at the 90-day mark, suggesting a pattern of selling before price declines; however, the cross-ticker track record shows an average 90-day return of +15.4% following sells, indicating mixed timing accuracy across holdings. The sale's magnitude and the substantial post-transaction retention of 6.38M shares signal a significant portfolio exit rather than full liquidation, occurring as the company reports $7.4B in latest-quarter revenue and $239.0M net income with +11.5% annual growth.

BCP 8 Holdings Mozart Manager LLC sold 33,317,824 shares ($1.2B) in 4 separate transactions at $36.54, reducing stake by -94.4%

BCP 8 Holdings Mozart Manager LLC executed 4 separate sales totaling 33,317,824 shares for $1,217,349,994.41, reducing its stake from 35,308,291 shares to 1,990,467 shares. The sales occurred at $36.54 per share, while the current price stands at $35.75, placing the stock -29.7% from its 52-week high of $50.88. Notably, the insider's prior 4 sales at MDLN were each well-timed at the 90-day mark (100.00% timing success rate at this ticker), with the pattern established by 4 identical transactions on 2026-03-10 each showing 90d returns of -9.8%, demonstrating the insider sold ahead of subsequent declines. The company's fundamentals show revenue of $7,352,000,000.00 with net income of $239,000,000.00 and annual revenue growth of +11.5%, yet the stock has declined -20.1% over 30 days and -19.5% over 90 days from this transaction date, establishing context for a near-complete exit position.

10% owner BX Mozart ML-2 Holdco LP sold 33,317,824 shares for $1,217,349,994.41 on 2026-05-28, reducing stake by 94.4%

BX Mozart ML-2 Holdco LP, a 10% owner of Medline, executed 4 separate sales on 2026-05-28 totaling 33,317,824 shares (33.32M shares) for $1,217,349,994.41 ($1.2B) at $36.54 per share, slashing its position from 35,308,291 shares to 1,990,467 shares post-transaction (a 94.4% reduction). This near-complete exit occurs as the stock trades 29.7% below its 52-week high of $50.88 and has declined 20.1% over 30 days and 19.5% over 90 days. The insider's cross-ticker track record shows 100.00% well-timed selling (4 prior sells with negative average 90-day returns), and at this ticker specifically, all 4 prior sells on 2026-03-10 were well-timed with -9.8% 90-day returns. The magnitude and near-complete nature of this liquidation, combined with consistent prior timing success and current downward momentum, suggests the insider is exiting a major position amid price deterioration.

10% owner BCP 8 Holdings Mozart Manager L.L.C. sells 27,852,986 shares for $1.1B at $40.51, reducing holdings by 92.0% to 2.43M shares

BCP 8 Holdings Mozart Manager L.L.C., a principal 10% shareholder in Medline Inc., executed 4 separate sales totaling 27,852,986 shares for $1,128,268,756.88 on 2026-03-10, reducing its stake from 30,281,667 shares to 2,428,681 shares—a 92.0% reduction in holdings. The sales occurred at $40.51 per share against a current market price of $41.07, with the stock down 9.3% over the prior 30 days and trading 17.8% below its 52-week high of $49.99. This near-complete exit by a major insider holder occurs while the company reports robust 11.5% annual revenue growth, creating a meaningful divergence between fundamental performance and the shareholder's decision to substantially liquidate.

TC Group Cayman sells 26,105,840 MDLN shares for $1.07B at $41.00; stake reduced to 125.45M shares (-17.2%)

TC Group Cayman, a 10% owner, executed a $1,070,339,440 sale of 26,105,840 shares on 2026-03-10 at $41.00, reducing its stake from 151,560,081 to 125,454,241 shares. The transaction represents a substantial 17.2% reduction in holdings and occurred at a price $0.07 below the current market price of $41.07 and 17.8% below the 52-week high of $49.99. Despite the large share disposition, the company's fundamentals show resilience with annual revenue growth of 11.5%, suggesting the sale was driven by portfolio allocation rather than operational distress.

Carlyle Group sold 26,105,840 shares of MDLN at $41.00 (-17.2% of holdings) for $1.07B on 2026-03-10

Carlyle Group, holding 10% ownership, executed a substantial open-market sale of 26.11M shares (26,105,840 shares) on 2026-03-10 at $41.00 per share, reducing its stake from 151.56M to 125.45M shares. The stock has since declined 9.3% over the prior 30 days and currently trades at $41.07, down 17.8% from its 52-week high, suggesting the timing may have been favorable relative to recent price pressure. Carlyle's cross-ticker track record shows a 47.06% well-timed rate on prior sells with positive 12.1% 30-day average returns, though this same-ticker transaction represents only the second disclosed sale at MDLN following a December 2025 sale that showed strong 30-day performance of 52.1%. The sale occurs against a backdrop of MDLN's solid 11.5% annual revenue growth, yet the large reduction in Carlyle's ownership stake warrants investor attention given the magnitude of shares exited and the insider's historically successful timing patterns.

CP Circle ML Holdco GP, LLC sold 26,105,840 shares of MDLN at $41.00 for $1,070,339,440.00 on 2026-03-10

CP Circle ML Holdco GP, LLC, a 10% owner of Medline Inc., executed a substantial sale of 26,105,840 shares at $41.00, reducing holdings by 17.2% from 151.56M to 125.45M shares. This represents a material partial liquidation of the fund's position at a price $0.07 below current market ($41.07) and 17.8% below the 52-week high of $49.99, occurring amid a 9.3% price decline over the prior 30 days. The transaction's size ($1.1B) and timing relative to a 30-day downturn warrant examination of whether this reflects a shift in the fund's capital allocation strategy or portfolio positioning, particularly given the company's solid 11.5% annual revenue growth, which does not indicate operational distress.

H&F Capital Partners X sold 26.13M MDLN shares for $1.1B at $40.51, reducing 10% stake by 77.1%.

Hellman & Friedman Capital Partners X, a 10% shareholder, executed 4 separate sales totaling 26,131,237 shares for $1,058,524,148.39 at $40.51 on 2026-03-10, reducing its position from 33,913,025 shares to 7,781,788 shares—a 77.1% reduction in holdings. The blended average price of $40.51 compares to a current price of $41.07, with the stock down 17.8% from its 52-week high and down 9.3% over the past 30 days. The filer's cross-ticker track record shows 3 prior sells with an average 30-day return of +55.5%, though this cross-ticker track record provides limited insight into timing patterns at this specific ticker; at MDLN itself, 0 of 0 prior sells were well-timed at the 90-day measurement. The substantial reduction in a major shareholder's stake, combined with recent 30-day price weakness and the stock trading below its 52-week high, merits investor attention to the motivations and any material developments at Medline that may have prompted this significant liquidation.